open access

Ahead of print
Case report
Published online: 2021-06-10
Get Citation

Recurrent Her-2 positive occult breast cancer presenting with zosteriform cutaneous metastases: a case report

Mehmet Zahid Kocak, Murat Araz, Mustafa Karaagac, Dilek Caglayan, Mustafa Korkmaz, Aykut Demirkiran
DOI: 10.5603/OCP.2021.0019

open access

Ahead of print
CASE REPORTS
Published online: 2021-06-10

Abstract

Various cutaneous metastasis patterns are described in breast cancer. Zosteriform metastases are rare cutaneous
metastases, which appear in a dermatomal distribution. A 66-year woman presented with a 1-month history
of nodular lesions on the left posterior hemithorax area. Biopsy was reported as human epidermal growth factor
receptor (Her) 2 positive, hormone receptor-negative breast carcinoma metastasis. Dual blockade therapy targeting
Her-2 overexpression was initiated for the patient. Treatment response was obtained after 3 cycles. There was
a significant improvement in skin lesions. Zosteriform cutaneous metastases can be the early sign of systemic
spread and can show an initial response to therapy. Therefore, physicians should perform an exhaustive physical
examination including that of skin.

Abstract

Various cutaneous metastasis patterns are described in breast cancer. Zosteriform metastases are rare cutaneous
metastases, which appear in a dermatomal distribution. A 66-year woman presented with a 1-month history
of nodular lesions on the left posterior hemithorax area. Biopsy was reported as human epidermal growth factor
receptor (Her) 2 positive, hormone receptor-negative breast carcinoma metastasis. Dual blockade therapy targeting
Her-2 overexpression was initiated for the patient. Treatment response was obtained after 3 cycles. There was
a significant improvement in skin lesions. Zosteriform cutaneous metastases can be the early sign of systemic
spread and can show an initial response to therapy. Therefore, physicians should perform an exhaustive physical
examination including that of skin.

Get Citation

Keywords

zosteriform; cutaneous metastases; recurrent; occult; breast cancer

About this article
Title

Recurrent Her-2 positive occult breast cancer presenting with zosteriform cutaneous metastases: a case report

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Case report

Published online

2021-06-10

DOI

10.5603/OCP.2021.0019

Keywords

zosteriform
cutaneous metastases
recurrent
occult
breast cancer

Authors

Mehmet Zahid Kocak
Murat Araz
Mustafa Karaagac
Dilek Caglayan
Mustafa Korkmaz
Aykut Demirkiran

References (16)
  1. Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: an overview. Dermatol Clin. 2008; 26(1): 1–15, vii.
  2. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993; 29(2 Pt 1): 228–236.
  3. De Giorgi V, Grazzini M, Alfaioli B, et al. Cutaneous manifestations of breast carcinoma. Dermatol Ther. 2010; 23(6): 581–589.
  4. Moore S. Cutaneous metastatic breast cancer. Clin J Oncol Nurs. 2002; 6(5): 255–260.
  5. Araújo E, Barbosa M, Costa R, et al. A First Sign Not to be Missed: Cutaneous Metastasis from Breast Cancer. Eur J Case Rep Intern Med. 2020; 7(1): 001356.
  6. Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol. 2007; 143(5): 613–620.
  7. Casimiro LM, Corell JJV. Metástasis cutáneas de neoplasias internas. Med Cutan Iber Lat Am. 2009; 37: 117–129.
  8. LeSueur BW, Abraham RJ, DiCaudo DJ, et al. Zosteriform skin metastases. Int J Dermatol. 2004; 43(2): 126–128.
  9. Virmani NC, Sharma YK, Panicker NK, et al. Zosteriform skin metastases: clue to an undiagnosed breast cancer. Indian J Dermatol. 2011; 56(6): 726–727.
  10. Sittart JA, Senise M. Cutaneous metastasis from internal carcinomas: a review of 45 years. An Bras Dermatol. 2013; 88(4): 541–544.
  11. Noguchi E, Kamio T, Kamio H, et al. Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report. Oncol Lett. 2014; 8(6): 2448–2452.
  12. Pizzuti L, Sergi D, Barba M, et al. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient. Tumori Journal. 2018; 99(3): e127–e130.
  13. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007; 13(6): 1663–1674.
  14. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006; 7(4): 354–359.
  15. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007; 117(8): 2019–2027.
  16. Graziano V, Scognamiglio MT, Zilli M, et al. Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? Cancer Biol Ther. 2015; 16(12): 1704–1709.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl